Company: IMCR
Filing Date: 2025-03-17
Form Type: 424B7
Source: 0001140361-25-008917
Chunk: 18

Company: Immunocore Holdings plc
Filing Date: 2025-03-17
Form: 424B7
Chunk 18
---
 in the United States. Any final and conclusive monetary judgment for a definite sum obtained against us in U.S. courts would be treated by the courts of the United Kingdom as a cause of action in itself and sued upon as a debt at common law so that no retrial of the issues would be necessary, provided that certain requirements are met. Whether these requirements are met in respect of a judgment based upon the civil liability provisions of the U.S. securities laws, including whether the award of monetary damages under such laws would constitute a penalty, is an issue for the court making such decision. If an English court gives judgment for the sum payable under a U.S. judgment, the English judgment will be enforceable by methods generally available for this purpose. These methods generally permit the English court discretion to prescribe the manner of enforcement.

As a result, U.S. investors may not be able to enforce against us or our senior management, board of directors or certain experts named herein who are residents of the United Kingdom or countries other than the United States any judgments obtained in U.S. courts in civil and commercial matters, including judgments under the U.S. federal securities laws.

**Our ability to issue ADSs in connection with a conversion of notes may be limited in certain circumstances.**

Under English law, we must obtain shareholder authority to allot ordinary shares or grant rights to subscribe for or convert any security into ordinary shares. In addition, English law generally provides shareholders with preemptive rights when equity securities are allotted (which includes the grant of a right to subscribe for or convert any security into ordinary shares) for cash; however, it is possible for the articles of association, or shareholders at a general meeting representing at least 75% of our ordinary shares present (in person or by proxy) and voting at that general meeting, to disapply these preemptive rights. The number of ordinary shares represented by the ADSs deliverable upon conversion of the notes may not exceed the number of ordinary shares authorized by our shareholders to be issued and allotted by our board of directors free from preemptive rights and not previously used by our board of directors (the “allotment share cap”).

On February 3, 2021, our shareholders authorized our directors, for a period up to the close of business on February 2, 2026 to issue ordinary shares and to grant rights to subscribe for or convert any security into ordinary shares, up to an aggregate nominal amount of £150,000 (equivalent to 75,000,000 ordinary shares) and disapplied statutory